Wegovy Dose After 1 mg
After taking Wegovy 1 mg once weekly for 4 weeks, the next dose is 1.7 mg once weekly for another 4 weeks, followed by the final maintenance dose of 2.4 mg once weekly. 1, 2
Standard Titration Schedule
The FDA-approved titration schedule for Wegovy follows a structured 16-week escalation protocol designed to minimize gastrointestinal side effects while reaching the therapeutic maintenance dose 1, 2:
- Week 1-4: 0.25 mg once weekly
- Week 5-8: 0.5 mg once weekly
- Week 9-12: 1.0 mg once weekly (your current dose)
- Week 13-16: 1.7 mg once weekly (your next dose)
- Week 17 onward: 2.4 mg once weekly (maintenance dose) 1, 2
Key Implementation Points
The gradual dose escalation is critical for developing gastrointestinal tolerance. The most common adverse effects—nausea (44%), diarrhea (32%), vomiting (25%), and constipation (23%)—are significantly reduced through this slow titration approach 3. Each dose level should be maintained for at least 4 weeks before advancing 1, 2.
Some patients may achieve adequate weight loss at submaximal doses and can remain at that dose long-term rather than continuing escalation. 1, 4 If you experience strong therapeutic response at 1.7 mg with good tolerability, discuss with your provider whether continuing at that dose is appropriate rather than advancing to 2.4 mg.
Missed Dose Considerations
If you miss 2 or fewer consecutive doses at the 1 mg level: Resume at 1 mg if you previously tolerated it well, then continue the planned escalation to 1.7 mg after completing the appropriate duration 1, 4.
If you miss 3 or more consecutive doses: Restart the entire titration schedule from 0.25 mg to minimize gastrointestinal adverse effects 1, 2, 4. Jumping directly back to 1 mg or higher after prolonged interruption significantly increases the risk of severe nausea and vomiting.
Essential Concurrent Interventions
Wegovy must be combined with lifestyle modifications for optimal efficacy 2, 3:
- Caloric deficit: Minimum 500 kcal/day below total energy requirements 3
- Physical activity: Minimum 150 minutes weekly of structured exercise 3
- Behavioral counseling: Ongoing support for dietary and behavioral changes 3
Long-Term Treatment Expectations
Semaglutide should be considered lifelong therapy to maintain weight loss. Discontinuation results in significant weight regain, with participants in clinical trials regaining most of their lost weight after stopping the medication 2, 3. The average weight loss at the 2.4 mg maintenance dose is 14.9% of baseline body weight at 68 weeks, compared to 2.4% with placebo 5.
Monitoring During Dose Escalation
Evaluate gastrointestinal symptoms at each dose transition 3. If symptoms are severe at 1 mg, maintain that dose for an additional 4 weeks before attempting escalation to 1.7 mg 3. Monitor body weight every 4 weeks during titration 3.